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Summary
Background It has been suggested that intralesional triamcinolone injections repre-
sent a safe and effective therapeutic strategy in controlling the permanent disfigur-
ing swelling of orofacial granulomatosis (OFG). However, robust supporting
evidence is lacking, due to the variable and inconsistent design of available studies.
Objectives To investigate whether a standardized regimen of intralesional triamcin-
olone has beneficial long-term effects on orofacial swelling of OFG. We also
studied potential associations with a number of prognostic factors.
Methods We designed a retrospective observational study of a homogeneous cohort
of 22 well-phenotyped patients with OFG. The primary outcome was defined as a
statistically significant decrease in post-treatment disease severity. Statistically
significant association with prognostic factors was the secondary outcome. Statistical
analysis includedWilcoxon signed-rank tests and logistic regression.
Results Compared with pretreatment, there were statistically significant decreases
in disease severity scores at all time points until 48 months post-treatment
(P < 001). Logistic regression analysis showed there was no independent prog-
nostic variable of statistical significance (P > 005). The majority of patients (14/
22, 636%) received one course of intralesional triamcinolone and did not expe-
rience disease recurrence. The mean disease-free period after the first course of
intralesional therapy was 289  18 months (95% confidence interval 287–
291). No adverse effects were reported.
Conclusions This is the first study to have employed robust cohort methodology
and sound statistics to demonstrate long-term effectiveness of intralesional triam-
cinolone in controlling the disfiguring swelling of OFG. Because of limitations
inherent in observational studies, further research in the form of randomized
case-control trials is needed to confirm the present findings.
What’s already known about this topic?
• It has been suggested that intralesional corticosteroid therapy is effective in control-
ling the permanent disfiguring swelling of orofacial granulomatosis (OFG); how-
ever, robust supporting evidence is lacking due to the variable and inconsistent
design of available studies.
What does this study add?
• This is the first cohort study on intralesional therapy to employ robust cohort
design, consistent methodology and a standardized regimen of triamcinolone injec-
tions. It provides reliable evidence of long-term effectiveness in reducing the orofa-
cial swelling of OFG.
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Orofacial granulomatosis (OFG) is a chronic immunologically
mediated granulomatous disorder that typically affects the oro-
facial region. The spectrum of possible clinical manifestations
of OFG ranges from subtle oral mucosal swelling and recur-
rent ulceration to permanent fibrous swelling of the lips and
face; neurological manifestations can also occur.1–3 Although
variable and multiform in its early stages,3,4 the natural his-
tory of OFG is ultimately progressive, and permanent disfigur-
ing labial and/or facial swelling eventually develops in nearly
all affected individuals.2–4 Indeed, labial and facial swelling
represents the most common reason for which patients with
OFG seek medical attention5 and is the major culprit in
reduced quality of life and psycho-social distress associated
with the disease.6
Long-term remission of the orofacial swelling of OFG by
means of intralesional triamcinolone acetonide injections was
first reported in 1992 by Sakuntabhai et al.7 A number of sub-
sequent independent reports have further suggested their clini-
cal benefit and overall safety.8–20 However, there is little
robust evidence, as available studies are limited by uncon-
trolled design, small sample size, short-term follow-up and
wide variability in administration schedule, drug concentra-
tion, concomitant medications, total dose of injected corticos-
teroids, OFG diagnostic criteria and outcome measures.8–13
In order to clarify the long-term effectiveness of intralesion-
al triamcinolone in the treatment of OFG-related orofacial
swelling, we retrospectively studied a homogeneous cohort of
well-phenotyped patients with idiopathic OFG who had been
homogeneously managed with a predefined therapeutic regi-
men of triamcinolone injections and reviewed long-term with
a predefined set of outcome measures. The present study is
reported according to STrengthening the Reporting of OBser-
vational studies in Epidemiology (STROBE) recommenda-
tions.21
Patients and methods
Study cohort and data extraction
The study cohort consisted of 22 individuals diagnosed with
OFG and treated with intralesional triamcinolone acetonide
therapy2,3 at the Oral Medicine Unit of the Eastman Dental
Hospital, University College London Hospital Trust between
January 2006 and July 2012. Diagnostic and inclusion criteria
are reported in Table 1. In order to minimize selection bias,
all patients with idiopathic OFG consecutively treated with int-
ralesional therapy from 2006 and 2012 were included in the
present cohort study. Systematic data extraction of detailed
patient phenotype and management was performed in order
to minimize information bias. The following data were
extracted from hospital notes: patient demographics, date of
disease onset and disease duration before treatment, number
and location of orofacial sites involved, date, number of
courses and total dose of intralesional corticosteroid therapy,
disease-free period and recurrences, length of observation per-
iod and adverse events.
Intralesional triamcinolone acetonide therapy
All patients were treated with at least one full course of int-
ralesional corticosteroid injections using highly concentrated
triamcinolone acetonide 40 mg mL1.11 The therapeutic
regimen is described in Figures 1 and 2. We used a 1 mL sub-
cutaneous syringe and no trigeminal nerve anaesthetic block. A
thin film of anaesthetic cream was applied onto the affected
lip immediately before the injections in most patients. After
completion of one full course, post-treatment hospital appoint-
ments were arranged at 2 weeks and 1 month from comple-
tion of therapy, followed by reviews at 6-monthly intervals.
Further courses of therapy were performed in case of recurrent
disease occurring more than 6 months after treatment comple-
tion. Patients experiencing recurrences or disease progression
within the first 6 months after therapy were offered alternative
treatment options (not reported in this study).
Primary outcome and outcome measure
The primary aim of this study was to investigate whether int-
ralesional triamcinolone therapy has beneficial long-term effects
upon the orofacial swelling of OFG. The primary outcome was
defined as a statistically significant decrease in disease severity
post-treatment, compared with pretreatment and between
review appointments at 2 weeks, 1 month and every 6 months
after therapy. A dedicated four-point disease severity score was
used as the outcome measure (Table 2). The disease severity
score was attributed on the basis of (i) the clinician’s judge-
ment during a hospital appointment, (ii) the patient’s own
opinion, (iii) four standardized clinical photographs (frontal
face, frontal lips, left face and right face), taken before therapy
and during review appointments and used to support the clini-
cian’s and patient’s judgement in allocating outcome scores to
each time point. Clinical photographs of each patient’s face
prior to OFG onset, where available, were used for comparison.
Secondary outcome
The secondary aim was to investigate the potential association
between primary outcome and multiple confounding prognos-
tic factors. Confounding prognostic factors were defined as
Table 1 Diagnostic and inclusion criteria
Presence of permanent swelling of orofacial tissues due to
orofacial granulomatosis
Orofacial granulomatosis diagnosed on the bases of currently
accepted criteria2,3
No history and no clinical evidence of Crohn disease or
sarcoidosis
No reported clear history of hypersensitivity to cinnamon and
benzoate
Lack of response to topical corticosteroids or
immunosuppressants
No concomitant systemic/topical corticosteroid or other
immunosuppressive therapy
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disease, patient or treatment-related covariates (Table 2) that
could potentially influence OFG response to intralesional ther-
apy. The secondary outcome was defined as a statistically sig-
nificant association between post-therapy disease severity
status and any of the possible confounding factors.
Ancillary outcomes
Ancillary outcomes included length of disease-free period after
the first and additional courses of intralesional therapy, time to
outcome, number and timing of recurrences and adverse effects.
Statistical analysis
Primary outcome
Pairwise comparisons of score between pre- and correspond-
ing post-treatment at 2 weeks, 1, 6, 12, 18, 24, 30, 36, 42,
48, 54, 60, 66 and 72 months were performed using a series
of Wilcoxon signed-rank tests, with an adjusted significance
level of 001 for multiple testing. All analyses were conducted
using SPSS version 20.0 (IBM, Armonk, NY, U.S.A.).
Secondary outcomes
Longitudinal disease severity scores from the initial to the
most recent time points were clustered at the individual
patient level. Repeated measures univariable longitudinal ordi-
nal logistic regression analysis was performed with the disease
severity score as the dependent variable and each of the prog-
nostic confounding factors as independent variables (Table 2).
The intention was to enter independent variables with statisti-
cally significant odds ratios at the 10% level in the univariable
regression analyses into a multivariable regression analysis
using a significance level of 5%. Robust standard errors were
employed to take into account the longitudinal nature of the
Fig 1. Regimen of intralesional injections of
triamcinolone acetonide
Fig 2. Sites of intralesional injections in a
patient with swelling of upper and lower lip.
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data and all analyses were conducted using Stata version 11.0
(StataCorp, College Station, TX, U.S.A.).
Ancillary analyses
Descriptive analyses were performed to report ancillary outcomes.
We considered disease-free those patients who had post-treat-
ment disease severity score 0 (no swelling) or 1 (mild, aestheti-
cally acceptable swelling requiring no therapy) and calculated the
length of disease-free period after the first course of intralesional
therapy and subsequent to additional courses in individuals who
had disease recurrences. We also calculated the time needed for
patients to become disease-free (time to outcome).
Disease recurrence was defined as development of clinically
significant swelling (e.g. disease severity score 2 or 3) subse-
quent to the completion of a full course of intralesional ther-
apy and after at least 6 months of disease severity 0 or 1.
Adverse effects during and after intralesional triamcinolone
injections were recorded.
Results
Details of study cohort
There was no information missing in the data collected, and
full details of the study cohort are provided in Table 3. There
were five (23%) female and 17 (77%) male patients, with
mean age 391  221 years [95% confidence interval (CI)
388–394]. The mean disease duration before intralesional
therapy was 603  866 months (95% CI 591–614). In
particular, before receiving intralesional corticosteroid, the vast
majority of patients (19, 86%) had had OFG for at least
12 months, and more than half of them (12, 54%) for
36 months or longer. Three patients (4%) had had OFG for
less than a year and about one-third (6, 27%) for more than
6 years, before commencing intralesional therapy.
The observation period after completion of the first course of
intralesional treatment ranged from 13 to 72 months with a
mean of 393  179 months (95% CI 391–395). Data from
review appointments were available for analysis at the follow-
ing time points: 2 weeks, 1, 6 and 12 months (22/22 patients,
100%), 18 months (21/22, 95%), 24 months (17/22, 77%),
30 months (16/22, 73%), 36 months (12/22, 55%),
42 months (10/22, 45%), 48 months (9/22, 41%),
54 months (7/22, 32%), 60 months (5/22, 23%), 66 months
(2/22, 9%) and 72 months (1/22, 5%). Therefore, review
data for up to 24 months post-treatment were available for the
vast majority (> 70%) of patients and for up to 36 months for
more than half of them (> 50%). Approximately a quarter of
patients were observed for more than 5 years.
Regarding topography and extension of orofacial swelling,
approximately half of the patients had OFG limited to a single
labial or facial site, whilst the remaining patients had multi-
ple-site involvement. Twelve (55%) patients had one site
affected by OFG: upper lip (four patients, 18%), lower lip
(seven patients, 32%) and right face (one patient, 4%). The
remaining 10 patients (45%) had more than one site affected:
both lips (five patients, 23%) and combined labial and facial
swelling (five patients, 23%).
The total number of courses of intralesional injections
performed was 30, with a mean of 145  07 (95% CI 144–
146). The majority of patients (14/22, 64%) had a single
course, six (27%) had two courses, and only two (9%) had
three courses. All courses but one consisted of three consecutive
weekly sessions of injections. The mean dose of triamcinolone
per session was 055  02 (95% CI 046–065), equivalent to
22  8 mg (range 184–26). The mean cumulative dose per 3-
week full course was 168  06 mL (95% CI 138–197),
equivalent to 672  24 mg (95% CI 552–788). The mean
total cumulative dose per patient, including treatment of recur-
rences, was 239  14 mL (95% CI 237–240), equivalent to
956  56 mg (95% CI 948–96).
Primary outcome: changes in disease severity score
Compared with pretreatment, there was a statistically significant
decrease in disease severity scores at all post-treatment time points,
i.e. 2 weeks, 1, 6, 12, 18, 24, 30, 36, 42 and 48 months
(P < 001) (Table 4; Fig. 3). Results after 48 months were cen-
sored due to the small number of patients.
Secondary outcome: association with prognostic
confounding factors
The results of the univariable analyses showed no statistically
significant association between any independent variable and
the severity score (P > 01) with the exception of ‘Total num-
ber of courses of therapy’ (P < 01). Post hoc multivariable
regression analysis was not indicated as there was only one
relevant factor emerging from univariable analysis; no inde-
pendent variable was therefore statistically significant at the
5% level (Table 5).
Table 2 Outcome measure and prognostic factors
Disease severity score
0 No swelling
1 Mild swelling – aesthetically acceptable
and requiring no treatment.
2 Moderate swelling
3 Severe swelling
Prognostic factors
Patient-related factors Age
Gender
Disease-related factors Duration of disease before treatment
Severity of disease before treatment
Number of affected orofacial sites
Presence or absence of facial
(nonlabial) swelling
Treatment-related factors Total dosage of triamcinolone
Total number of courses of therapy
Observation period after first
course of treatment
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Ancillary outcomes
Disease recurrence
Fourteen individuals (64%) of the study cohort had not expe-
rienced any recurrence of orofacial swelling at the time of data
collection. Among the eight patients (36%) who did experi-
ence disease recurrence, six (6/22, 27%) had only one recur-
rence occurring at month 6 (n = 1), 12 (n = 2), 18 (n = 1),
30 (n = 1) and 36 (n = 1). Two individuals (2/22, 9%) had
two disease recurrences each occurring at 6 and 18 months
and 18 and 36 months respectively.
Disease-free period
The mean disease-free period after the first course of
intralesional therapy was 289  18 months (95% CI 287–
291). The eight individuals who experienced disease
recurrence and received a second course of intralesional ther-
apy had a subsequent mean disease-free period of
283  172 months (95% CI 279–287). The two individu-
als who experienced two disease recurrences and received a
third full course of intralesional therapy had an additional
mean disease-free period of 15  42 months (95%
CI 148–152).
Time to outcome
The vast majority of patients (20/22; 91%) reached disease-
free status at 2 weeks after the first course of therapy. All
patients did so at 1 month after treatment. Patients who expe-
rienced recurrent disease reached disease-free status at
6 months after additional courses of therapy.
Table 4 Comparison between pre- and
corresponding post-treatment disease status
scores
Time points after
first treatment Patients (n) Median Minimum Maximum
Adjusted
P-value*
Pretreatment 22 3 2 3
2 weeks 22 0 0 2 < 0001
1 month 22 0 0 1 < 0001
6 months 22 0 0 3 < 0001
12 months 22 0 0 2 < 0001
18 months 21 0 0 3 < 0001
24 months 17 0 0 1 < 0001
30 months 16 0 0 1 < 0001
36 months 12 0 0 2 < 0001
42 months 10 0 0 1 0002
48 months 9 0 0 1 0004
54 months 7 0 0 1 0016
60 months 5 0 0 1 0063
66 months 2 0 0 0 0500
72 months 1 0 0 0 Not available
*Significant results, P < 001.
(a)
(b)
Fig 3. Frontal and lateral views of lip swelling
before (a) and after (b) intralesional therapy.
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Adverse effects
There were no significant adverse effects, with patients report-
ing only minimal transient discomfort associated with the
injections. No patient reported short-term transient worsening
of orofacial swelling immediately after the injections, and
there were no cases of perioral steroid-induced cutaneous
hyperpigmentation.
Discussion
Treatment of the disfiguring orofacial swelling of OFG has
proven exceedingly difficult and remains unsatisfactory.22 A
recent review of the literature concluded that no uniform and
predictable therapeutic model has been demonstrated to be
effective in reducing the permanent labial or facial enlarge-
ment of OFG.22 Immunosuppressants, tumour necrosis factor
alpha inhibitors and other agents, as well as surgical cheilopl-
asty (reviewed in Banks et al.),22 have been used as single or
combined therapy with some positive, although overall incon-
sistent, results in a variety of cases reports and small case ser-
ies.22 Similarly, the encouraging results of a benzoate- and
cinnamon-free diet reported by White et al.23 have never been
replicated by other groups and need further research.
Currently, corticosteroids remain the mainstay of OFG man-
agement in many treatment regimens and can be provided
either topically, systemically or as intralesional therapy.22 The
latter was initially introduced in 1971,24 and almost 20 years
later was modified by Sakuntabhai et al.,7 who reported remis-
sion of lip swelling for up to 10–12 months. Intralesional ther-
apy was further modified in subsequent years with the
introduction of highly concentrated triamcinolone acetonide
(40 mg mL1). This formulation allows injection of a high
dose of triamcinolone within a reduced drug volume, thereby
increasing efficacy, reducing associated pain and avoiding the
need for anaesthetic block.8–11 However, there remains wide
variety and little consistency among studies regarding the best
intralesional triamcinolone regimen to adopt. Significant differ-
ences exist in administration schedules, drug concentration,
concomitant medications and total dose of injected corticoster-
oids.8–13 Evidence is also limited by small sample size, OFG
diagnostic criteria, outcome measures and short-term follow-
up.8–13 A recent review concludes that although success of int-
ralesional triamcinolone has been reported, it is often tempo-
rary and the long-term efficacy remains unclear.22
The present study, although being limited by its retrospec-
tive and noncomparative design, is characterized by a number
of methodological strengths leading to more robust conclu-
sions than in previous publications.
This is the largest cohort of patients with OFG treated with
intralesional triamcinolone injections and the only study that
adopted a standardized therapeutic regimen of single agent int-
ralesional, highly concentrated triamcinolone acetonide with
minimal variability of dosage among patients. Indeed, the mean
cumulative dose per patient per 3-week full course was
168  06 mL and the mean total cumulative dose, including
treatment of recurrences, was 239  14 mL. In contrast, pre-
vious studies were either single case reports, small case series or
failed to use a well-defined, consistent single-agent treatment
regimen with homogeneous triamcinolone dosage throughout
the study cohort.8–10,13–20 Mean post-treatment observation
ranged from 13 to 72 months with a mean of 393  179,
therefore assuring assessment of long-term outcomes.
Another robust feature of the present study is its homo-
geneous cohort. All patients were carefully phenotyped so as to
include only individuals with idiopathic OFG and exclude those
with evidence of systemic granulomatous disease (e.g. Crohn
disease or sarcoidosis). Also, we included all consecutive
patients with idiopathic OFG referred to our unit, including
those with a long history of persistent orofacial swelling (mean
disease duration being 603  866 months) and failure of
other topical and systemic therapies (including corticosteroids),
who are traditionally considered difficult to manage due to per-
manent fibrotic changes of affected tissues. Exclusion of these
patients, as done by other authors,8 carries the risk of affecting
study outcomes due to biased selection of individuals with
short-term, treatment-free disease who are more likely to
respond to any given therapy. In addition, some of the perceived
benefits of therapy could, in fact, represent spontaneous fluctua-
tions of the disease, which are well known to occur, especially
in the early stages of OFG as part of its natural history.3
We adopted a predefined four-point disease severity system
as an outcome measure that was based on clinicians’ and
patients’ judgement, as well as on clinical photographs.
The present study is the first to adopt sound and robust statis-
tics to assess primary and secondary treatment outcomes at pre-
defined time-points; the Wilcoxon signed-rank test is
Table 5 Relationship between longitudinal disease severity scores and
patient-, disease- and treatment-related prognostic confounding factors
(n = 22)
Independent variable
Odds
ratio
95% confidence
interval P-value
Patient-related
Age 1000 0981–1021 0961
Gender 1677 0892–3150 0108
Disease-related
Duration of disease
before treatment
1000 0995–1011 0440
Severity of disease
before treatment
0883 0364–2144 0783
Number of affected
orofacial sites
1060 0634–1772 0823
Presence or absence of
facial (nonlabial) swelling
1098 0386–3121 0861
Treatment-related
Total dose of
triamcinolone
1002 0996–1008 0441
Total number of
courses of therapy
1573 0946–2614 0081
Observation period after
first course of treatment
1010 0985–1036 0450
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appropriate for comparison of two sets of scores from the same
participants. We found that all patients of the cohort had a sta-
tistically significant reduction in their disease severity at all stud-
ied time points up to 4 years post-treatment, therefore
demonstrating the long-term clinical benefit of intralesional tri-
amcinolone therapy in reducing orofacial swelling and restoring
cosmetic appearance. Of note, logistic regression analysis
showed no association at the 5% level between disease severity
and prognostic confounding factors, therefore demonstrating
that likelihood of response to intralesional triamcinolone is not
dependent on factors such as duration and severity of disease
before therapy, number of affected orofacial sites, presence or
absence of facial (nonlabial) swelling, total dose of triamcino-
lone or total number of courses of therapy. There was also no
significant association with the length of observation period
after the first course of treatment, suggesting that the beneficial
effects of intralesional therapy can persist in the long term.
Descriptive analyses showed that the mean disease-free period
after the first course of intralesional therapy was
289  18 months, therefore confirming further its long-term
effectiveness. The majority of patients (14/22, 636%) remained
disease-free until data collection whereas approximately one-
third of patients (8/22, 364%) experienced disease recurrence
but responded to a second course of intralesional therapy with a
subsequent mean disease-free period of 283  172 months.
These data demonstrate that disease recurrence can be effectively
managed with a second course of intralesional triamcinolone and
the second disease-free period can last as long as the first one.
Out of these seven patients, two had a further disease recurrence
at 12 and 18 months after the second course of therapy and
responded to a third course of intralesional triamcinolone.
Analysis of time to outcome showed that the vast majority
of patients (20/22, 91%) reached disease-free status within
2 weeks from completion of intralesional therapy and all did
so within 4 weeks, thus demonstrating that intralesional tri-
amcinolone injections are fast acting in reducing orofacial
swelling in OFG.
In conclusion, the present study, although limited by its
observational, retrospective and single-arm design, employed a
robust cohort design and consistent methodology for the first
time in this field and provided sound evidence of the long-
term effectiveness of intralesional injections in reducing the
disfiguring orofacial swelling of OFG. Further research in the
form of well-designed case-control randomized trials is
needed to confirm the present data. Given the rarity of the
disease, multicentre collaboration is recommended.
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